Gwella Mushrooms Inc co-founder and CEO Peter Reitano tells Proactive the privately-held Toronto, Canada-based group has begun selling its pharmacologically-mimicked low dose of psilocybin nutraceutical called Mojo, which he says, aims to help with energy levels, focus, and mood modulation.
Reitano says the group recently close around $2 million from investors including The Conscious Fund and Vice Ventures to help it execute on Mojo sales and well as launch more products in the pipeline, all the while focusing in on US states showing signs of psychedelics legalization.